​

Eli Lilly (LLY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LLY Stock Forecast

Eli Lilly (LLY) stock forecast, based on 40 Wall Street analysts, predicts a 12-month average price target of $1,019.00, with a high of $1,146.00 and a low of $950.00. This represents a 38.66% increase from the last price of $734.90.

$550 $670 $790 $910 $1 $1 High: $1146 Avg: $1019 Low: $950 Last Closed Price: $734.9

LLY Stock Rating

Eli Lilly stock's rating consensus is Buy, based on 40 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 31 Buy (77.50%), 7 Hold (17.50%), 2 Sell (5.00%), and 0 Strong Sell (0.00%).

Buy
Total 40 0 2 7 31 Strong Sell Sell Hold Buy Strong Buy

LLY Price Target Upside V Benchmarks

TypeNameUpside
StockEli Lilly38.66%
SectorHealthcare Stocks 33.91%
IndustryDrug Manufacturers - General Stocks37.84%

Price Target Trends

1M3M12M
# Anlaysts-227
Avg Price Target-$1.05K$982.63
Last Closing Price$734.90$734.90$734.90
Upside/Downside-42.60%33.71%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 257164-128
Mar, 257165-129
Feb, 256146-127
Jan, 256156-128
Dec, 247166-130
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 06, 2025Morgan Stanley$1.15K$912.7625.55%55.94%
Jan 17, 2025Andrew BerensLeerink Partners$950.00$740.1528.35%29.27%
Jan 16, 2025Kerry HolfordBerenberg Bank$970.00$746.7429.90%31.99%
Oct 31, 2024Evan David SeigermanBMO Capital$1.01K$829.7421.72%37.43%
Oct 14, 2024Andrew BerensLeerink Partners$990.00$932.066.22%34.71%
Sep 13, 2024Peter VerdultCitigroup$1.06K$935.0213.37%44.24%
Aug 27, 2024Terence FlynnMorgan Stanley$1.11K$957.5115.51%50.50%
Aug 14, 2024Kerry HolfordBerenberg Bank$1.05K$908.0515.63%42.88%
Aug 12, 2024James ShinDeutsche Bank$1.02K$891.6814.95%39.47%
Aug 09, 2024Chris ShibutaniGoldman Sachs$856.00$891.68-4.00%16.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 17, 2025Leerink PartnersOutperformOutperformhold
Nov 18, 2024BMO CapitalOutperformOutperformhold
Oct 17, 2024BernsteinOutperforminitialise
Oct 14, 2024Leerink PartnersOutperformOutperformhold
Oct 03, 2024Raymond JamesUnderperformUnderperformhold
Sep 25, 2024Goldman SachsBuyBuyhold
Sep 20, 2024Deutsche BankBuyBuyhold
Sep 13, 2024BMO CapitalOutperformOutperformhold
Sep 09, 2024Wells FargoBuyBuyhold
Aug 27, 2024Deutsche BankBuyBuyhold

Financial Forecast

EPS Forecast

$5 $13 $21 $29 $37 $45 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.82$6.15$6.93$5.83$11.71----
Avg Forecast$7.37$8.13$7.64$6.23$12.95$22.49$29.14$34.70$41.01
High Forecast$8.20$9.04$8.56$6.58$13.35$27.77$33.34$41.05$43.17
Low Forecast$6.72$7.42$6.99$5.86$12.41$21.13$23.61$25.96$39.12
Surprise %-7.46%-24.35%-9.29%-6.42%-9.58%----

Revenue Forecast

$20B $35B $50B $65B $80B $95B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$24.54B$28.32B$28.54B$34.12B$45.04B----
Avg Forecast$24.38B$28.04B$28.59B$33.65B$45.31B$58.51B$70.05B$79.12B$89.33B
High Forecast$26.48B$30.46B$31.25B$33.90B$45.68B$59.01B$70.10B$79.63B$92.95B
Low Forecast$22.73B$26.15B$26.74B$33.44B$45.00B$58.02B$70.00B$78.61B$86.17B
Surprise %0.67%0.99%-0.17%1.40%-0.58%----

Net Income Forecast

$0 $8B $16B $24B $32B $40B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.19B$5.58B$6.24B$5.24B$10.59B----
Avg Forecast$5.39B$5.76B$5.98B$5.24B$11.63B$19.44B$24.80B$30.38B$37.04B
High Forecast$6.47B$6.92B$7.17B$6.29B$12.06B$25.08B$30.11B$37.08B$39.00B
Low Forecast$4.31B$4.61B$4.78B$4.19B$11.21B$19.09B$21.33B$23.45B$35.34B
Surprise %14.93%-3.15%4.45%--8.95%----

LLY Forecast FAQ

Is Eli Lilly stock a buy?

Eli Lilly stock has a consensus rating of Buy, based on 40 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 31 Buy, 7 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Eli Lilly is a favorable investment for most analysts.

What is Eli Lilly's price target?

Eli Lilly's price target, set by 40 Wall Street analysts, averages $1.02K over the next 12 months. The price target range spans from $950 at the low end to $1.15K at the high end, suggesting a potential 38.66% change from the previous closing price of $734.9.

How does Eli Lilly stock forecast compare to its benchmarks?

Eli Lilly's stock forecast shows a 38.66% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the drug manufacturers - general stocks industry (37.84%).

What is the breakdown of analyst ratings for Eli Lilly over the past three months?

  • April 2025: 25.00% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 3.57% Strong Sell.
  • March 2025: 24.14% Strong Buy, 55.17% Buy, 17.24% Hold, 0% Sell, 3.45% Strong Sell.
  • February 2025: 22.22% Strong Buy, 51.85% Buy, 22.22% Hold, 0% Sell, 3.70% Strong Sell.

What is Eli Lilly’s EPS forecast?

Eli Lilly's average annual EPS forecast for its fiscal year ending in December 2025 is $22.49, marking a 92.06% increase from the reported $11.71 in 2024. Estimates for the following years are $29.14 in 2026, $34.7 in 2027, and $41.01 in 2028.

What is Eli Lilly’s revenue forecast?

Eli Lilly's average annual revenue forecast for its fiscal year ending in December 2025 is $58.51B, reflecting a 29.89% increase from the reported $45.04B in 2024. The forecast for 2026 is $70.05B, followed by $79.12B for 2027, and $89.33B for 2028.

What is Eli Lilly’s net income forecast?

Eli Lilly's net income forecast for the fiscal year ending in December 2025 stands at $19.44B, representing an 83.61% increase from the reported $10.59B in 2024. Projections indicate $24.8B in 2026, $30.38B in 2027, and $37.04B in 2028.